Published in Prostate on April 02, 2012
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene (2012) 2.03
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene (2013) 1.29
MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J Biol Chem (2013) 1.09
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer (2014) 1.07
Emerging role of mucins in epithelial to mesenchymal transition. Curr Cancer Drug Targets (2013) 0.91
Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res (2015) 0.88
MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC. Mol Cancer Res (2014) 0.87
Pivotal role of MUC1 glycosylation by cigarette smoke in modulating disruption of airway adherens junctions in vitro. J Pathol (2014) 0.83
Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep (2015) 0.83
MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma. PLoS One (2015) 0.80
MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor. Prostate Cancer Prostatic Dis (2016) 0.77
Gene panel model predictive of outcome in patients with prostate cancer. OMICS (2013) 0.76
Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget (2016) 0.75
MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget (2016) 0.75
Origin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties. Sci Rep (2017) 0.75
Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells. Oncogenesis (2017) 0.75
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 5.31
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A (2007) 3.54
MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res (2005) 2.87
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
IAP regulation of metastasis. Cancer Cell (2010) 2.47
The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem (2001) 2.37
The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell (2007) 2.35
Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem (1997) 2.32
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene (2003) 2.30
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Linking beta-catenin to androgen-signaling pathway. J Biol Chem (2002) 2.27
Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem (2007) 2.23
The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem (2001) 2.19
MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell (2006) 2.15
Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res (2009) 2.04
MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res (2009) 2.04
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene (2010) 1.99
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem (2004) 1.82
Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res (2011) 1.80
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J (2009) 1.67
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 1.48
Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem (2006) 1.47
MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal (2011) 1.42
Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther (2009) 1.39
MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther (2009) 1.30
MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer (2010) 1.23
MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. Mol Urol (1999) 1.20
MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis (2006) 1.11
Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res (1997) 1.08
Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol (2011) 1.07
A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma (Larchmt) (2011) 1.01
Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther (2008) 1.00
MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer (2007) 0.96
ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res (2009) 0.95
MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res (2011) 0.95
Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo (2009) 0.91
Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol (2005) 0.90
PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res (2011) 0.88
Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate (2011) 0.87
Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene (2010) 0.86
Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study. Anal Quant Cytol Histol (2008) 0.82
Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission. Cell (2005) 3.93
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 3.55
MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res (2005) 2.87
JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol (2005) 2.56
The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell (2007) 2.35
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene (2003) 2.30
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell (2005) 2.23
Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem (2007) 2.23
MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell (2006) 2.15
MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol (2007) 2.15
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res (2009) 2.04
MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res (2009) 2.04
Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem (2003) 1.98
DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther (2003) 1.96
Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem (2006) 1.92
The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem (2004) 1.82
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res (2013) 1.75
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66
Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem (2002) 1.60
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood (2014) 1.60
MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther (2008) 1.51
Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem (2006) 1.50
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47
Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J (2003) 1.47
A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res (2008) 1.46
Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor. Cancer Biol Ther (2003) 1.44
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J (2006) 1.42
The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res (2003) 1.42
MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal (2011) 1.42
MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther (2003) 1.39
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res (2004) 1.36
Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res (2008) 1.36
Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res (2003) 1.34
MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem (2004) 1.33
MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol (2009) 1.33
MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem (2012) 1.31
MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther (2009) 1.30
Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res (2007) 1.27
MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res (2006) 1.27
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem (2003) 1.26
Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol (2011) 1.24
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol (2003) 1.23
MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer (2010) 1.23
c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol Cell Biol (2002) 1.22
Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem (2003) 1.22
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res (2012) 1.21
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood (2010) 1.20
Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene (2006) 1.19
Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther (2004) 1.18
Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem (2003) 1.18
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood (2011) 1.15
p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem (2002) 1.12
Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage. J Biol Chem (2002) 1.11
Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother (2012) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res (2008) 1.10
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood (2002) 1.10